Coagulation Factor Ix (Recombinant), Fc Fusion Protein

Introduction Overview

Generic Name

Coagulation Factor IX (Recombinant), Fc Fusion Protein

Brand Name

Alprolix

Dosage Form

Lyophilized powder for solution for intravenous injection

Drug Class

Miscellaneous coagulation modifiers

Pharmacokinetics

Absorption

Alprolix, administered intravenously, exhibits complete bioavailability with immediate systemic presence following infusion. Given its intravenous route, absorption phase typical of oral or subcutaneous drugs is bypassed, ensuring rapid onset of action essential for acute management of bleeding episodes in hemophilia B patients.

Distribution

After intravenous administration, Alprolix distributes primarily within the plasma compartment. Its large molecular size and proteinaceous nature restrict distribution mainly to intravascular space with minimal extravascular penetration. The fusion of Factor IX to the Fc domain extends its plasma half-life via interaction with the neonatal Fc receptor (FcRn), facilitating recycling and decreased lysosomal degradation, thus enhancing systemic exposure and prolonging dosing intervals.

Metabolism

Metabolic clearance of Alprolix occurs primarily via proteolytic degradation pathways typical of plasma proteins. The Fc fusion allows interaction with FcRn-mediated salvage pathways, reducing its catabolism. The drug is not subject to cytochrome P450 enzyme metabolism, minimizing risk of hepatic metabolic drug interactions. The metabolic pathways involve enzymatic cleavage in liver and reticuloendothelial system cells to amino acids and peptides, which are subsequently recycled or excreted.

Elimination

Elimination of Alprolix is predominantly through proteolytic catabolism rather than renal or hepatic excretion. The Fc fusion prolongs its half-life to allow dosing intervals as long as 7-10 days in adults. Clearance rates are influenced by presence of inhibitors or neutralizing antibodies. The extended half-life reduces infusion frequency, improving patient adherence and quality of life.

Dosage Forms

Adults

Adults and adolescents aged 12 years and older are commonly initiated on routine prophylaxis dosing at 50 IU/kg once weekly or 100 IU/kg once every 10 days, adjustable based on individual pharmacodynamic response and bleeding phenotype. For on-demand bleeding control, initial doses targeting FIX levels of 30-60 IU/dL for minor/moderate bleeding and 80-100 IU/dL for major bleeding are recommended, with dosing intervals customized accordingly.

Adolescents

Dosing for adolescents parallels adult regimens, with initiation of prophylactic therapy at 50 IU/kg once weekly or 100 IU/kg every 10 days, allowing flexibility to accommodate adolescent growth and lifestyle. On-demand and perioperative dosing follows adult guidance, tailored to bleeding severity and surgical invasiveness.

Special Populations

Pediatric patients under 12 years require more frequent or higher dosing with initial prophylaxis at 60 IU/kg once weekly, given higher clearance and metabolic activity in children. No specific renal or hepatic dosing adjustments are established due to primary proteolytic elimination. Patients with inhibitors to FIX may exhibit reduced efficacy, necessitating close monitoring. Pregnant or breastfeeding patients lack sufficient data; use is warranted only if clearly needed with careful risk-benefit evaluation.

Mechanism Of Action

Alprolix is a recombinant fusion protein comprising coagulation Factor IX linked to the Fc domain of human immunoglobulin G1 (IgG1). Factor IX is an essential serine protease in the intrinsic pathway of the coagulation cascade. Upon activation, Factor IXa complexes with Factor VIIIa on phospholipid surfaces to activate Factor X, culminating in thrombin generation and fibrin clot formation essential for hemostasis. By supplementing deficient or dysfunctional endogenous Factor IX in hemophilia B patients, Alprolix restores this vital enzymatic activity, correcting the coagulation defect.

The Fc fusion protein design utilizes the natural salvage pathway mediated by the neonatal Fc receptor (FcRn), resulting in prolonged plasma half-life compared to conventional recombinant Factor IX products. This prolongation allows less frequent dosing and sustained hemostatic levels. The molecular fusion does not impair the functional clotting activity of Factor IX but enhances pharmacokinetic properties, improving patient adherence and clinical outcomes.

Intravenous administration of Alprolix leads to immediate replacement of circulating Factor IX. The recombinant nature ensures product purity and minimizes viral transmission risks associated with plasma-derived factors. Functionally, Factor IX in Alprolix requires activation by Factor XIa or the tissue factor-Factor VIIa complex to its enzymatically active form. It then participates in the assembly of the intrinsic tenase complex, a critical amplifier of coagulation, leading to thrombin and fibrin clot formation.

Clinically, Alprolix’s mechanism facilitates prevention and treatment of bleeding episodes related to hemophilia B by normalizing coagulation. Comparative studies demonstrate its extended half-life offers superior dosing convenience over standard recombinant Factor IX therapies. Extensive clinical trials support its efficacy and safety profile in acute and prophylactic settings.

Pharmacological Actions

Replacement of deficient coagulation Factor IX in hemophilia B patients
Activation to Factor IXa to initiate intrinsic coagulation pathway
Fc fusion-mediated prolongation of plasma half-life via FcRn interaction
Enhancement of thrombin generation through intrinsic tenase complex formation
Facilitation of fibrin clot formation and hemostasis
Reduction of bleeding episode frequency with routine prophylaxis
Rapid on-demand control of bleeding episodes
Support for perioperative hemostatic management

Therapeutic Clinical Uses

Treatment and control of bleeding episodes in hemophilia B (congenital Factor IX deficiency)
Routine prophylaxis to prevent bleeding episodes in patients with hemophilia B
Perioperative management to prevent and control bleeding during and after surgery
Management of bleeding associated with trauma in hemophilia B patients
Replacement therapy in patients with low or absent endogenous Factor IX levels
Alternative to plasma-derived Factor IX concentrates reducing infection risk
Use in both pediatric and adult populations with hemophilia B
Supportive therapy to reduce morbidity and mortality associated with bleeding complications

Side Or Adverse Effects

Nausea
Headache
Dizziness
Altered sense of taste (dysgeusia)
Mild skin rash at injection site
Injection site pain, redness, itching, or stinging
Risk of allergic reactions including hives, wheezing, and swelling of face or throat
Potential for inhibitor development to Factor IX reducing efficacy
Signs of excessive blood clotting such as numbness, weakness, chest pain, or leg swelling
Fever or chills post-infusion
Weight gain and swelling in waist, hands, or legs indicating fluid retention
Continued or new bleeding despite treatment
Infusion site reactions including irritation and localized discomfort
Possible hypersensitivity reactions to excipients

Precautions

Inform healthcare provider of any history of allergic reactions to Factor IX products
Monitor for development of neutralizing antibodies (inhibitors) to Factor IX
Use cautiously in patients with known cardiovascular disease due to thrombosis risk
Ensure proper aseptic technique during reconstitution and administration to prevent infections
Frequent monitoring of coagulation parameters and Factor IX activity levels recommended
Adjust dosing regimens in pediatric patients based on pharmacokinetic response
Avoid use beyond expiration date or if reconstituted solution is cloudy or contains particulates
Educate patients about signs of hypersensitivity and thrombosis
Pregnancy and lactation safety not established; use only if benefits justify risks
Advise patients to carry medical identification indicating bleeding disorder status
Avoid concomitant use with other coagulation products unless directed by healthcare provider

Warnings

Contraindicated in patients with known hypersensitivity to Alprolix or its components
Risk of severe allergic or anaphylactic reactions requiring emergency intervention
Potential development of inhibitors to Factor IX that may render treatment ineffective
Monitor for signs of excessive clotting (thrombosis) which can cause stroke or myocardial infarction
Use in patients with Factor IX inhibitors may result in diminished therapeutic response
Do not administer via routes other than intravenous injection
Proper storage required to maintain drug stability and efficacy
Do not mix with other medicinal products in the same infusion tubing or container
Immediate medical attention required for severe infusion reactions
Use caution in patients with renal or hepatic impairment due to lack of specific data
Ensure blood tests to evaluate Factor IX activity and inhibitor development during therapy

Contraindications

Known hypersensitivity to Alprolix or any component of the formulation
Allergy to recombinant coagulation Factor IX products
Presence of neutralizing antibodies (inhibitors) against Factor IX without ability to control
Situations requiring alternative hemostatic agents not responsive to Factor IX replacement
Use outside the indicated population without consulting a specialist
Concomitant use with incompatible medications that may interfere with coagulation assessment
Severe allergic reactions to previous Factor IX administrations

Drug Interactions

No known drug interactions with Alprolix reported at this time
Not metabolized by cytochrome P450 enzymes, minimizing interaction potential
Caution with concomitant use of other procoagulant or anticoagulant agents until clinical monitoring performed
No interactions with common over-the-counter medications or supplements established
Potential additive thrombogenic risk if used with other hemostatic drugs or antifibrinolytics
No known interaction with vaccines or gene therapies in hemophilia B
Patients should report all concomitant medications to healthcare providers
No known interactions with foods or beverages

Preparations Of The Drug

Lyophilized powder for solution for intravenous injection
Available in single-use vials to be reconstituted with provided diluent syringe
Packaging includes vial adapter and diluent for aseptic preparation
Instructions for Use including reconstitution and administration guide provided
Reconstituted solution appears clear to slightly opalescent and colorless
Dosing strength vials vary and require individual calculation based on patient weight and required IU
Stable under refrigeration at 2°C to 8°C with allowance for limited room temperature storage up to 30°C for 6 months
After reconstitution, solution can be stored at room temperature up to 3 hours prior to administration
Designed for intravenous infusion via syringe and infusion set
Supplied by Bioverativ Therapeutics Inc., a Sanofi company